> Novartis is teaming up with MIT to develop new ways to manufacture drugs. The company will give the university $65 million over 10 years to create a new research program. Report [1]
> Galvus, a once-daily oral treatment for type 2 diabetes, has been approved by the EMEA. Release [2]
> Celera has earned a clinical milestone payment of $2 million from Merck. The payment was triggered by Merck's advancement of odanacatib into a Phase III clinical trial as a potential treatment for osteoporosis. Release [3]
> Scientists at the Institute for Neurodegenerative Disorders report that they have identified a drug that could potentially treat the cognitive disorders associated with schizophrenia. Report [4]
> A new study concludes that two enzymes--SIRT3 and SIRT4--play a key role in mitochondria, regulating the aging process. Report [5]
And Finally... Researchers at Texas A&M University are participating in developing a medicine that is worth sneezing about: a treatment for influenza that forms a jelly when sprayed into the nose. Release [6]
Links:
[1] http://www.fiercepharma.com/story/novartis-mit-overhaul-manufacturing/2007-09-28
[2] http://www.pharmalive.com/News/index.cfm?articleid=479340
[3] http://www.fiercebiotech.com/press-releases/press-release-celera-announces-clinical-milestone-payment-merck
[4] http://www.fiercebioresearcher.com/story/new-therapy-found-schizophrenia/2007-09-25
[5] http://www.fiercebioresearcher.com/story/anti-aging-study-finds-enzymes-protect-cells/2007-09-25
[6] http://www.fiercebiotech.com/press-releases/press-release-nosespray-vaccine-using-aloe-vera-has-exciting-potential